Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease and Up to Three Years of an Open-Label Extension With Active Study Treatment

Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease and Up to Three Years of an Open-Label Extension With Active Study Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SCarlet RoAD
  • Sponsors Roche
  • Most Recent Events

    • 16 Apr 2018 According to the Genentech media release, data from this study will be presented in a platform session at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
    • 14 Mar 2018 According to a MorphoSys media release, data from this study will be presented at the upcoming Alzheimer's and Parkinson's Disease conference AAT-AD/PDTM Focus Meeting 2018.
    • 27 Feb 2018 Planned End Date changed from 22 Jul 2020 to 20 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top